Hepatopancreatic manifestations in atypical hemolytic uremic syndrome
PDF (Español (España))

Keywords

atypical hemolytic uremic syndrome
hepatitis
pancreatitis
eculizumab
mutation

How to Cite

1.
Vargas D, Castillo Arteaga M, Sánchez Tordecilla MM. Hepatopancreatic manifestations in atypical hemolytic uremic syndrome. Rev. Colomb. Nefrol. [Internet]. 2022 Oct. 7 [cited 2022 Nov. 26];9(3). Available from: https://revistanefrologia.org/index.php/rcn/article/view/595

Abstract

Introduction: Atypical hemolytic uremic syndrome is a severe and orphan disease, in its atypical variety courses with extrarenal clinical manifestations. The presence of gastrointestinal compromise is infrequent, but the prognosis is unfavorable, since they have more relapses and higher mortality. Therefore, it is important that physicians are trained in recognizing the rare manifestations of this pathology, in order to improve the outcome in these patients.

Purpose: This case illustrates a unique case in terms of symptoms and etiology not previously described.

Case presentation: We report the case of an 8-year-old male who presented with fever, jaundice, abdominal and lumbar pain, diarrhea, hematemesis, and hematuria. Atypical hemolytic uremic syndrome was diagnosed. He presented clinical deterioration with multiple organ involvement, documenting high blood pressure and acute kidney injury, who received management with crystalloids and diuretics without improvement, requiring renal replacement therapy and multiple transfusional support. However, there was still no clinical improvement, so the start of recombinant humanized IgG monoclonal antibody was indicated, with satisfactory outcomes.

Discussion and conclusions: This case is a clear example that extrarenal and multi-organ involvement can be the main manifestation of this disease, so it is important that clinicians are aware of the clinical course that may develop a patient with atypical presentations, in order to avoid diagnostic and therapeutic delays. Likewise, the etiological approach is important in order to provide an accurate prognosis to the patient and his family.

https://doi.org/10.22265/acnef.9.3.595
PDF (Español (España))

References

Provaznikova D, Rittich S, Malina M, Seeman T, Marinov I, Riedl M, et al. Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. Pediatr Nephrol. 2011;27:73-81. https://doi.org/10.1007/s00467-011-1943-5

Atkinson JP, Liszewski MK, Richards A, Kavanagh D, Moulton EA. Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue. Ann N Y Acad Sci. 2005;1056:144-52. https://doi.org/10.1196/annals.1352.032

Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13(3):663-75. https://doi.org/10.1111/ajt.12077

Sheerin NS, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM. 2016;109(1):27-33. https://doi.org/10.1093/qjmed/hcv082

Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost. 2014;12(9):1440-8. https://doi.org/10.1111/jth.12615

Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11):643-657. https://doi.org/10.1038/nrneph.2012.214

Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64(4):633-7. https://doi.org/10.1053/j.ajkd.2014.01.434

Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267-79. https://doi.org/10.1182/blood-2005-10-007252

Fidan K, Göknar N, Gülhan B, Melek E, Yildirim Z, Baskin E, et al. Extra-Renal manifestations of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2018;33(8):1395-403. https://doi.org/10.1007/s00467-018-3933-3

Yong-Biau C, Kun-Feng L, Chun-Hung C, Zhi-Hong W, Xian-Yong L. Thrombotic thrombocytopenic purpurahemolytic uremic syndrome: Pathogenesis and therapy. J Intern Med Taiwan. 2013;24(4):299-308.

Nickavar A, Sotoudeh K. Assesment, treatment and prevention of atypical hemolytic uremic syndrome. Int J Prev Med. 2013;4(1):6-14.

Polito MG, Kirsztajn GM. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome. J Bras Nefrol. 2010;32(3):303-15.

Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-62. https://doi.org/10.2215/CJN.04760512

Yasuda K, Sasaki K, Yamato M, Rakugi H, Isaka Y, Hayashi T, et al. Atypical hemolytic uremic syndrome with MCP mutations preceded by respiratory infection. CEN Case Rep. 2013;2(1):34-7. https://doi.org/10.1007/s13730-012-0034-1

Lapeyraque AL, Bitzan M, Al-Dakkak I, Francis M, Huang S, Kaprielian R, et al. Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome. Can J Kidney Health Dis. 2020;7. https://doi.org/10.1177/2054358119897229

Hofer J, Rosales A, Fischer C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr. 2014;2:97. https://doi.org/10.3389/fped.2014.00097

Bianchi L, Gaiani F, Vincenzi F, Kayali S, Di Mario F, Leandro G, et al. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases. Acta Biomed. 2018;89(9-S):153-7. https://doi.org/10.23750/abm.v89i9-s.7911

Wijnsma KL, Duineveld C, Wetzels JF, van de Kar NC. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2019;34(11):2261-77. https://doi.org/10.1007/s00467-018-4091-3

Fakhouri F, Frémeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med. 2013;24(6):492-5. https://doi.org/10.1016/j.ejim.2013.05.008

Liszewski MK, Atkinson JP. Complement regulator CD46: genetic variants and disease associations. Hum Genomics. 2015;9(1):7. https://doi.org/10.1186/s40246-015-0029-z

Richards A, Kathryn-Liszewski M, Kavanagh D, Fang C, Moulton E, Fremeaux-Bacchi V, et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol. 2007;44(1-3):111-22. https://doi.org/10.1016/j.molimm.2006.07.004

Macia M, de Alvaro-Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyer C, et al. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10(3):310-9. https://doi.org/10.1093/ckj/sfw115

Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, et al. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. Clin J Am Soc Nephrol. 2017;12(1):50-9. https://doi.org/10.2215/CJN.06440616

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dimensions


PlumX


Downloads

Download data is not yet available.